BioVaxys details shareholder value with retention of Maxim to achieve US stock exchange listing

About this update from Biovaxys Technology Corp

[{"type":"text","content":"BioVaxys details shareholder value with retention of Maxim to achieve US stock exchange listing\n \n \n (NewsDirect)\n \n \n \n \n BioVaxys CEO James Passin joins Natalie\nStoberman from the 35th International Papillomavirus Conference in\nWashington, D.C. to discuss its latest news of retaining New York\nCity-based Maxim Group as its financial advisor and investment banker.\n \n \n Passin says Maxim will handle\nstrategic planning, assessment of potential strategic alliances and\ncapital requirements, and advising the company with respect to the\nprocess of obtaining a listing on a US national stock exchange.\n \n \n BioVaxys is a clinical stage biotechnology company that is\ndeveloping viral and oncology vaccine platforms, as well as\nimmuno-diagnostics. The company is advancing vaccines for SARS-CoV-2,\nSARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized\nviral protein technology, and is planning a clinical trial of its\nhaptenized autologous cell vaccine used in combination with anti-PD1\nand anti-PDL1 checkpoint inhibitors that will initially be developed\nfor Stage III/Stage IV ovarian cancer.\n \n \n \n Contact\nDetails\n \n \n \n Proactive Canada\n \n \n +1 604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":1683,"tagName":"div"}]

More updates from Biovaxys Technology Corp